AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as shown:

Please delete the paragraph on page 3, lines 20-31 and replace it with the following paragraph:

According to a particularly advantageous method of embodiment of the invention, the peptide belonging to the UCP family is characterized in particular by the fact that it is selected from peptides corresponding to the ID ~~N°~~ NO sequence:

1) Pro Leu Asp Thr Ala Lys Val Arg Leu Gln (SEQ ID NO: 1)

2) Pro Thr Glu Val Ala Lys Val Arg Phe Gln (SEQ ID NO: 2)

3) Pro Thr Asp Val Ala Lys Val Arg Leu Gln (SEQ ID NO: 3)

4) Pro Thr Glu Val Ala Lys Val~~ley~~ Arg Leu Gln (SEQ ID NO: 4)

5) Pro Thr Asp Val Ala Lys Val~~ley~~ Arg Phe Gln (SEQ ID NO: 5)

6) Pro Val Asp Val Val Lys Thr Arg Phe Ile (SEQ ID NO: 6)

7) Pro Val Asp Val Val~~ley~~ Lys Thr Arg Tyr Met (SEQ ID NO: 7)

8) Pro Val Asp Val Val Lys Thr Arg Phe Met (SEQ ID NO: 8)

9) Pro Val Asp Val Val Lys Thr Arg Tyr Ile (SEQ ID NO: 9)

Please delete the paragraph on page 4, lines 1-3 and replace it with the following paragraph:

In addition, according to a highly preferred method of embodiment of the invention, the peptide fragment from the UCP family has as a sequence ID NO ~~N°~~(1), i.e. the sequence Pro-Leu-Asp-Thr-Ala-~~Lily~~Lys-Val~~ley~~-Arg-Leu-Gln (SEQ ID NO: 1).

Please delete the paragraph on page 7, lines 1-6 and replace it with the following paragraph:

More precisely, the present invention aims at using at least one protein of the UCP family, peptide fragments, or biologically active derivatives, as previously defined, as a slimming agent likely to be used particularly in the field of cosmetics. The invention relates to, in the same way, the use of peptides, such as those previously defined, as a slimming agent. According to a current preferred method of embodiment of the invention, the slimming active agent is the peptide having ~~the sequence ID N°(1)~~ (SEQ ID NO: 1).

Please delete the paragraph on page 14, lines 4-9 and replace it with the following paragraph:

The test was carried out on differentiated 3T3-L1 cells. These adipocytes were treated with the peptide of ~~sequence ID N°(1)~~ (SEQ ID NO: 1), i.e. of sequence Pro-Leu-Asp-Thr-Ala-Lys-Val-Arg-Leu-Gln, representative of the peptide family according to the invention, placed in a 0.5% solution at 50 ppm, for periods of 15 minutes, 30 minutes, or 1 hour. In parallel, differentiated 3T3-L1 cells were also treated with isoproterenol (an agent that induces lipolysis), at 1µM, thus forming a

positive control.

Please delete the paragraph on page 14, line 25 to page 15, line 8 and replace it with the following paragraph:

The aim of this study was to determine the influence of the peptide according to the invention on the quantity of intracellular ATP. The study was carried out using an "ATP Bioluminescence Assay HS II" kit. Differentiated 3T3-L1 cells were treated with a 0.5% solution at 50 ppm, containing the peptide of SEQ ID NO: 1~~sequence ID N°(1)~~, representative of the peptide family according to the invention, for a period up to 96 hours. At the end of the incubation time, the wells were emptied of their medium and were rinsed with 2 ml of cold PBS before adding 250 µl of lysis buffer, provided by the kit. The cells were then scraped, and then collected separately in 14 ml tubes. Each well was rinsed with 2 x 500 µl of cold PBS and everything was again collected in the respective tubes. Each tube was then placed in the polytron for 10 seconds at 18000 rpm. From these samples, a dilution of 1/12000, using cold PBS, was carried out before each reading. ATP quantity assessment was performed on these samples: 50 µl of this dilution were placed in a luma-basin and 50 µl of luminol were added. The reading of luminescence started after 10 seconds. The values were standardized compared to the quantity of proteins for each sample. Measurements were taken using a Biocounter M2010A LUMAC ®/ 3M.